Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 24/4/2019
SIETES contiene 92718 citas

 
 
 1 a 20 de 344 siguiente >>
Presentar resultados
Seleccionar todas
2.Enlace a cita original Cita con resumen
Rodríguez-Martín S, Martín-Merino E, Lerma V, Rodríguez-Miguel A, González O. Incidence of Stevens-Johnson syndrome/toxic epidermal necrolysis among new users of different individual drugs in a European population: a case-population study. Eur J Clin Pharmacol 2019;75:febrero. [Ref.ID 103013]
3.Enlace a cita original Cita con resumen
Shenoy ES, Macy E, Rowe T, Blumenthal KG. Evaluation and management of penicillin allergy. A review. JAMA 2019;321:15 de enero. [Ref.ID 103008]
4.Enlace a cita original Cita con resumen
Lovegrove MC, Geller AI, Fleming-Dutra KE, Shehab N, Sapiano MRP, Budnitz DS. US emergency department visits for adverse drug events from antibiotics in children, 2011–2015. J Pediatric Infect Dis Soc 2018:23 de agosto. [Ref.ID 102811]
5. Cita con resumen
Anónimo. Pneumonies communautaires peu graves chez les enfants. Prescrire 2018;38:518-23. [Ref.ID 102764]
6.Enlace a cita original Cita con resumen
Pasternak B, Inghammar M, Svanström H. Fluoroquinolone use and risk of aortic aneurysm and dissection: nationwide cohort study. BMJ 2018;360:8 de marzo. [Ref.ID 102640]
7. Cita con resumen
Laatikainen O, Mietttunen J, Sneck S, Lehtiniemi H, Tenhunen O, Turpeinen M. The prevalence of medication-related adverse events in inpatients-a systematic review and meta-analysis. Eur J Clin Pharmacol 2017;73:1539-49. [Ref.ID 102145]
8. Cita con resumen
Trubiano JA, Adkinson NF, Phillips EJ. Penicillin allergy Is not necessarily forever. JAMA 2017;318:82-3. [Ref.ID 102053]
9. Cita con resumen
Greenway T, Ross JS. US drug marketing: how does promotion correspond with health value?. BMJ 2017;357:j1855. [Ref.ID 101571]
10. Cita con resumen
Gisbert JP, Molina-Infante J. Tratamiento actual de la infección por Helicobacter pylori. Med Clin (Barc) 2017;148:20-2. [Ref.ID 101339]
11. Cita con resumen
Liou J-M, Fang Y-J, Chen C-C, Bair M-J, Chang C-Y, Lee Y-C, Chen M-J, Tseng C-H, Hsu Y-C, Lee J-Y, Yang T-H, Luo J-C, Chang C-C, Chen Y-N, Sheu B-S, Lin J-T, Wu J-Y, El-Omar EM, Wu M-S, Taiwan Gastrointestinal Disease and Helicobacter Consortium. Concomitant, bismuth quadruple, and 14-day triple therapy in the first-line treatment of Helicobacter pylori: a multicentre, open-label, randomised trial. Lancet 2016;388:2355-65. [Ref.ID 100981]
13. Cita con resumen
Diacon AH, van der Merwe L, Barnard M, von Groote-Bidlingmaier F, Lange C, García-Basteiro AL, Sevene E, Ballell L, Barros-Aguirre D. ß-lactams against tuberculosis — New trick for an old dog?. N Engl J Med 2016;375:393-4. [Ref.ID 100492]
14. Cita con resumen
Anónimo. Alternatives to fluoroquinolones. Med Lett Drugs Ther 2016;58:75-6. [Ref.ID 100457]
15. Cita con resumen
Zhang F, Mamtani R, Scott FI, Goldberg DS, Haynes K, Lewis JD. Increasing use of prescription drugs in the United Kingdom. Pharmacoepidemiol Drug Saf 2016;25:628-36. [Ref.ID 100019]
16. Cita con resumen
Hesdorffer CS, Longo DL. Drug-induced megaloblastic anemia. N Engl J Med 2015;373:1649-58. [Ref.ID 99629]
17. Cita con resumen
Romano A, Gaeta F, Valluzzi RL, Maggioletti M, Zaffiro A, Caruso C, Quaratino D. IgE-mediated hypersensitivity to cephalosporins: cross-reactivity and tolerability of alternative cephalosporins. J Allergy Clin Immunol 2015;136:685-91. [Ref.ID 99527]
18.Tiene citas relacionadas Cita con resumen
Li B-Z, Threapleton DE, Wang JY, Xu J-M, Yuan J-Q, Zhang C, Li P, Ye Q-L, Guo B, Mao C, Ye DQ. Comparative effectiveness and tolerance of treatments for Helicobacter pylori: systematic review and network meta-analysis. BMJ 2015;351:h4052. [Ref.ID 99413]
19.Tiene citas relacionadas Cita con resumen
Braden B. The best and worst treatments for Helicobacter pylori. BMJ 2015;351:h4146. [Ref.ID 99411]
20. Cita con resumen
Anónimo. Ceftobiprole médocaril. Prescrire 2015;35:331-5. [Ref.ID 99133]
Seleccionar todas
 
 1 a 20 de 344 siguiente >>